Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival (Q44362904)

From Wikidata

Jump to navigation Jump to search

scientific article published on 22 August 2013

Language	Label	Description	Also known as
English	Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival	scientific article published on 22 August 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

1 reference

based on heuristic

inferred from title

6

object named as

Patrick Y Wen

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Alona Muzikansky

4

object named as

Alona Muzikansky

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

author name string

Christina Chen

1

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Raymond Huang

2

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Ainsley MacLean

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Srinivasan Mukundan

5

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Andrew D Norden

7

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

22 August 2013

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Journal of Neuro-Oncology

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

115

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

267-276

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Advances in MRI assessment of gliomas and response to anti-VEGF therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Prediction of glioblastoma multiform response to bevacizumab treatment using multi-parametric MRI.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Diffusion-weighted imaging with calculated apparent diffusion coefficient of enhancing extra-axial masses

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Apparent diffusion coefficient of human brain tumors at MR imaging

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Minimum apparent diffusion coefficients in the evaluation of brain tumors

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Grading astrocytic tumors by using apparent diffusion coefficient parameters: superiority of a one- versus two-parameter pilot method

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1225-0

21 January 2018

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974656

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Apparent diffusion coefficients for differentiation of cerebellar tumors in children.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974656

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974656

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11060-013-1225-0

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44362904&oldid=2206592593"